Precision BioSciences, Inc.

237 articles about Precision BioSciences, Inc.

• Precision BioSciences to Present at Hep-DART 2023

  11/30/2023

  Precision BioSciences, Inc. today announced that the company will present at Hep-DART 2023 in an industry session and host a poster presentation on December 5, 2023, in Los Cabos, Mexico.

• Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

  11/28/2023

  Precision BioSciences, Inc. today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award to a new employee.

• Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

  11/13/2023

  Precision BioSciences, Inc. announced that the company will present late-breaking data at the American Association for the Study of Liver Diseases’ The Liver Meeting being held in Boston, MA.

• Precision BioSciences to Present at Upcoming Sidoti Conference

  11/10/2023

  Precision BioSciences, Inc. announced that the Company will present at the Sidoti November Micro Cap Conference taking place November 15-16, 2023.

• Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

  11/9/2023

  Precision BioSciences, Inc. today announced that an abstract featuring preclinical data for its wholly owned PBGENE-HBV program has been accepted for late-breaker presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Boston, MA on November 10-14, 2023.

• Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update

  11/7/2023

  Precision BioSciences, Inc. announced financial results for the third quarter ended September 30, 2023 and provided a business update.

• Precision BioSciences to Report Third Quarter Results on November 7, 2023

  11/1/2023

  Precision BioSciences, Inc. today announced that it will publish financial results for the third quarter 2023 and provide a business update on November 7, 2023.

• Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

  10/26/2023

  Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress.

• Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference

  10/23/2023

  Precision BioSciences, Inc. today announced that the Company will present at the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference taking place October 25, 2023.

• Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

  10/12/2023

  Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress.

• Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases

  9/27/2023

  Precision BioSciences, Inc. today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 18/161,560, titled “Engineered Meganucleases That Target Human Mitochondrial Genomes.”

• Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments

  9/12/2023

  Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments.

• Precision BioSciences to Attend and Present at Upcoming September 2023 Investor Conferences

  9/6/2023

  Precision BioSciences, Inc., a gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies, announced that members of management will participate in the following investor conferences in the month of September.

• Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023

  8/31/2023

  Precision BioSciences, Inc., a gene editing company developing ARCUS®-based in vivo gene editing therapies, announced that it will host its in vivo gene editing R&D Day on Tuesday, September 12, 2023 from 9:00-11:30 AM ET.

• Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer

  8/15/2023

  Precision BioSciences, Inc. (Nasdaq: DTIL) today announced completion of a strategic transaction with Imugene Limited (ASX: IMU) for global rights to Azercabtagene Zapreleucel (azer-cel), Precision’s lead allogeneic CAR T candidate, for cancer. Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment.

• Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update

  8/4/2023

  Precision BioSciences, Inc. today announced financial results for the second quarter ended June 30, 2023 and provided a business update.

• Precision BioSciences to Report Second Quarter Results on August 4, 2023

  8/1/2023

  Precision BioSciences, Inc., a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, announced that it will publish financial results for the second quarter 2023 and provide a business update on August 4, 2023.

• Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day

  7/27/2023

  Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day.

• Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023

  6/22/2023

  Precision BioSciences Announces Oral Presentation of Positive ARCUS ® Gene Editing Data at International Liver Congress 2023.

• Precision BioSciences to Present at Upcoming June Investor Conferences

  6/5/2023

  Precision BioSciences, Inc. today announced that members of management will participate in the following investor conferences in June 2023.